Sydney: Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling ...
Jan 29 (Reuters) - Medical device maker ResMed (RMD.N), opens new tab on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...
SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for ...
ResMed Inc. (NYSE:RMD) presented its second-quarter fiscal year 2026 results on January 29, 2026, showcasing strong financial performance with revenue growth of 9% at constant currency. Despite ...
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, ...
RMD is trading in the middle of its 52-week range and near its 200-day simple moving average. Price change The price of RMD shares has increased $2.83 since the market last closed. This is a 1.10% ...
ResMed Inc.’s RMD adjusted earnings per share (EPS) in the third quarter of fiscal 2025 were $2.37, up 11.3% year over year. The metric beat the Zacks Consensus Estimate by 0.4%. (Find the latest EPS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results